CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib

Published:2024-06 Issue:2 Volume:1 Page:100014
ISSN:2950-3280
Container-title:Blood Neoplasia
language:en
Short-container-title:Blood Neoplasia

Author:

Kok Chung Hoow^ORCID,Irani Yazad^ORCID,Clarson Jade,Saunders Verity,Dang Phuong,Shanmuganathan Naranie^ORCID,Branford Susan^ORCID,Yeung David^ORCID,Yong Agnes S. M.,Hughes Timothy P.

Funder

NHMRC

Publisher

Elsevier BV

Reference54 articles.

1. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV;Hehlmann;J Clin Oncol,2014

2. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors;Marin;J Clin Oncol,2012

3. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline;Branford;Blood,2014

4. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia;Hochhaus;Leukemia,2020

5. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors;Hughes;Blood,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP